Lastly, CSF1R inhibitors applied in conjunction with tau immunotherapy may prove to be a successful combination therapy; because microglia are not needed for antibody effector function79, removing tauopathy-activated microglia would slow tau pathogenesis and may also increase the efficacy of tau immunotherapy. The gene discussed is MAPT; the disease is tauopathy.